Boceprevir Patent Expiration

Boceprevir is Used for treating chronic Hepatitis C genotype 1 infection in adult patients with compensated liver disease. It was first introduced by Merck Sharp And Dohme Corp in its drug Victrelis on May 13, 2011.


Boceprevir Patents

Given below is the list of patents protecting Boceprevir, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Victrelis US7772178 Pharmaceutical formulations and methods of treatment using the same Nov 11, 2027 Merck Sharp Dohme
Victrelis US8119602 Administration of HCV protease inhibitors in combination with food to improve bioavailability Mar 17, 2027 Merck Sharp Dohme
Victrelis USRE43298 Peptides as NS3-serine protease inhibitors of hepatitis C virus Dec 22, 2024 Merck Sharp Dohme



A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Boceprevir's patents.

Given below is the list recent legal activities going on the following patents of Boceprevir.

Activity Date Patent Number
Patent litigations
Expire Patent 12 Sep, 2022 US7772178
Maintenance Fee Reminder Mailed 28 Mar, 2022 US7772178
Expire Patent 30 Mar, 2020 US8119602
Maintenance Fee Reminder Mailed 14 Oct, 2019 US8119602
Payment of Maintenance Fee, 8th Year, Large Entity 17 Jan, 2018 US7772178
Patent Issue Date Used in PTA Calculation 21 Feb, 2012 US8119602
Recordation of Patent Grant Mailed 21 Feb, 2012 US8119602
Issue Notification Mailed 01 Feb, 2012 US8119602
Dispatch to FDC 03 Jan, 2012 US8119602
Petition Decision - Dismissed 22 Dec, 2011 US8119602


Boceprevir's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List